Agile Therapeutics (NASDAQ:AGRX) CEO Al Altomari sat down with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco. New Jersey-based Agile is focused on seeking FDA approval of its lead drug Twirla, and is looking forward to its Feb 16 PDUFA date
viewAgile Therapeutics
Agile Therapeutics looks forward to Feb 16 PDUFA date
Quick facts: Agile Therapeutics
Price: 3.02 USD
NASDAQ:AGRX
Market: NASDAQ
Market Cap: $254.04 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Agile Therapeutics named herein, including the promotion by the Company of Agile Therapeutics in any Content on the Site, the Company receives...
FOR OUR FULL DISCLAIMER CLICK HEREDeep dive
Agile Therapeutics preps for commercialization of contraceptive skin...
Most read
Industry & services
Tesla shares tumble below level from before S&P 500 inclusion
6 days, 6 hours ago
Health
Coronavirus: Pfizer vaccine proves highly effective in real-world study,...
4 days, 9 hours ago
Health
MGC Pharmaceuticals reports strong financial position as it drives medical...
3 days, 13 hours ago
